| Document |
Document Title |
|
WO/2023/091990A1 |
The present disclosure provides compounds that block and/or disrupt GABA signaling. The disclosed compounds can decrease and/or inhibit activity, function, expression, and/or accumulation of GAD1, GABABR, and/or GABA and can be used in c...
|
|
WO/2023/090391A1 |
The purpose of the present disclosure is to provide: a method for testing for the presence/absence of hypertension, and the severity or prognosis thereof; a pathological animal model for pulmonary arterial hypertension (PAH); and a preve...
|
|
WO/2023/090409A1 |
In one embodiment, the present invention pertains to a peptide having affinity for the human transferrin receptor, and to applications of the same, wherein in order to pass through the blood-brain barrier, the peptide can be used by bind...
|
|
WO/2023/091746A1 |
The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
|
|
WO/2023/089612A1 |
The invention generally concerns peripherally restricted CB1 antagonists for treatment of LUTS.
|
|
WO/2023/090381A1 |
Disclosed is a new anti-HBV agent targeting host factor DOCK11. This anti-HBV agent contains, as an active ingredient, a substance which binds to DOCK11 and inhibits the function of DOCK11. In one embodiment, the anti-HBV according to th...
|
|
WO/2023/089544A1 |
The present invention relates to a pharmaceutical composition comprising an endolysin or an artilysin and an anti-cancer agent. In addition, the present invention relates to a pharmaceutical composition according to this invention for us...
|
|
WO/2023/090366A1 |
The present invention addresses the problem of providing an anticancer agent and/or a cardiac-function-improving agent having a novel action mechanism. A pharmaceutical composition containing, as an active ingredient, a substance that in...
|
|
WO/2023/088086A1 |
The present invention relates to a pair of tissue factors and an application thereof. The tissue factors are respectively TRIM31 and RHBDF2 which are derived from hepatic cells, and the TRIM31 and the RHBDF2 have a trade-off relationship...
|
|
WO/2023/085397A1 |
Provided is a detection method for Hunner-type interstitial cystitis diagnosis markers, the detection method detecting, from the urine of a subject, the presence amount of at least one microorganism selected from the group consisting of ...
|
|
WO/2023/082242A1 |
Provided in the present invention is the use of CTD-2256P15.2 and an encoding micropeptide thereof as a target in the development of a tumor treatment drug. Further provided in the present invention are the following uses of a CTD-2256P1...
|
|
WO/2023/086343A1 |
The present invention is directed to compositions comprising PLA2 inhibitors and optionally a metalloprotease inhibitor and/or an antivenom, antibody, antibody fragment or antibody derivative for topical, transdermal, buccal or sublingua...
|
|
WO/2023/083890A1 |
The invention relates to the use of compounds that reduce the signaling pathway induced by CLEC-1 /TRIM21 interaction, in particular compounds that antagonize the interaction, in particular the binding between CLEC-1 and TRIM21, the use ...
|
|
WO/2023/086927A1 |
Disclosed herein is a composition comprising a signal transducer and activator of transcription 3 (STAT3) inhibitor and one or more of a UNC51-like 1 (ULK1) inhibitor, histone deacetylase (HDAC) inhibitor, or an mTOR inhibitor in a pharm...
|
|
WO/2023/086796A2 |
Provided are methods for treating cancer by converting tumor-resident macrophages into a hybrid M1/M2 macrophage phenotype; this phenotype has attributes that are advantageous for cancer therapy. Hybrid markers include (lower than M2, hi...
|
|
WO/2023/083361A1 |
Disclosed is a new method for improving the quality of platelets. It is disclosed for the first time that the molecular of carnitine palmitoyl transferase II (CPT2) of the platelet mitochondrial inner membrane is critical to the survival...
|
|
WO/2023/086768A1 |
Disclosed herein are methods and compositions for inhibiting, preventing, ameliorating, reducing, or treating cardiovascular diseases, for example, stroke, traumatic brain injury, cerebral amyloid angiopathy, atherosclerosis, myocardial ...
|
|
WO/2023/083295A1 |
The present disclosure relates to ester derivatives of N 4-hydroxycytidine (NHC), to pharmaceutical compositions comprising thereof, to the preparation method thereof, and to the use and method of the ester derivatives of N 4-hydroxycyti...
|
|
WO/2023/083102A1 |
The present invention relates to the technical field of medicines, and provides a lipiodol-based active metal microsphere or nano-hydride composite embolic agent, a preparation method therefor and an application thereof. The composite em...
|
|
WO/2023/086562A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient comprising administration of the SSAO inhibitor: or a pharmaceutically accept...
|
|
WO/2023/084198A1 |
The present disclosure relates to a method of treating or preventing a disease in an individual, the method comprising reducing pyroptosis by administering to the individual a composition comprising an agent whose administration reduces ...
|
|
WO/2023/082055A1 |
The present invention relates to a pharmaceutical composition containing a β-lactam compound of formula (I), or a stereoisomer, a solvate or a pharmaceutically acceptable salt or ester thereof, and a lactamase inhibitor or efflux pump i...
|
|
WO/2023/086561A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an SSAO inhibitor and...
|
|
WO/2023/084531A1 |
The invention discloses herein related to synergistic combination of exogenous bioactives for activating intracellular secondary messenger (cAMP) signalling pathway. Particularly, the invention relates to synergistic compositions compris...
|
|
WO/2023/084459A1 |
This invention relates to methods of treating a method of treating a patient infected with SARS-CoV-2 comprising administering to the patient in need of such treatment a therapeutically effective amount of pexmetinib, or a pharmaceutical...
|
|
WO/2023/085440A1 |
Provided is a therapeutic agent or the like that is for refractory viral infections and that is capable of eliminating or decreasing cccDNA in hepatocytes. This therapeutic agent for refractory viral infections according to the present i...
|
|
WO/2023/061485A9 |
Provided are a rejuvenated skeletal muscle cell, a method for producing the rejuvenated skeletal muscle cell, and the use thereof.
|
|
WO/2023/083296A1 |
The present application provides the use of a PDE4 inhibitor (e.g., a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof) in the preparation of a drug for reducing uric acid levels and preventing uric acid lev...
|
|
WO/2023/084515A1 |
The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical...
|
|
WO/2023/086433A1 |
Pharmaceutical compositions comprising (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a carbonic anhydrase inhibitor (CAI) and methods of treating conditions associated with central hypoventilation are described herein.
|
|
WO/2023/079428A1 |
The present disclosure relates to combination therapies useful for the treatment of cancers. The combination therapy comprises a PD-1 axis binding antagonist, in combination with a Toll-like receptor 7/8 (TLR7/8) agonist or a pharmaceuti...
|
|
WO/2023/080895A1 |
Provided herein are pharmaceutical compositions comprising: (a)a natural killer cell (NK cell) comprising a KIR-B haplotype and expression of a CD16 molecule; and (b)a bispecific antibody or antigen binding fragment thereof comprising a ...
|
|
WO/2023/081486A1 |
The present disclosure relates to combination therapies with Cbl-b inhibitor compounds, and compositions and kits comprising combinations with the Cbl-b compounds. Also provided are methods of using the combinations with Cbl-b compounds ...
|
|
WO/2023/081757A1 |
The present disclosure relates to PI3Ka inhibitors, the crystalline forms, salts, and cocrystals thereof, and the compositions and methods of making and use thereof.
|
|
WO/2023/078881A1 |
The present invention is directed to (3R)-N-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)o
xy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, wherein th...
|
|
WO/2023/080263A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cataract, the composition comprising a substance for increasing expression of NFAT5 mRNA or protein, thereby inhibiting necrosis of crystalline lens...
|
|
WO/2023/078464A1 |
Disclosed are an epsilon-poly-L-lysine-based drug conjugate, an intermediate thereof, and an application thereof. The present invention provides an epsilon-poly-L-lysine derivative-drug conjugate that has a controllable group coupling nu...
|
|
WO/2023/081117A1 |
Provided herein are methods of improving sensitivity to immune checkpoint blockade (ICB) in a subject with a solid tumor cancer, the method comprising: administering to the subject with a solid tumor cancer an inhibitor of a tumor immune...
|
|
WO/2023/078557A1 |
The present invention provides methods and systems for the treatment of patients suffering from a condition characterized by the presence of vitreous floaters in the patients' eye and includes a ready-to-use topical ophthalmic formulatio...
|
|
WO/2023/081901A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2023/080765A1 |
The present invention pertains to an oxadiazole derivative and a composition containing same for preventing or treating NADPH oxidase (NOX)-related diseases. The present invention can be used to treat NADPH oxidase (NOX)-related diseases...
|
|
WO/2023/003815A9 |
In some aspects, the disclosure relates to compositions and methods for decreasing a risk of telangiectasia in a patient receiving a therapeutically effective amount of an ActRII polypeptide, particularly a dosing regimen that decreases ...
|
|
WO/2023/077413A1 |
Provided are a protein containing an amino acid sequence capable of binding to a peptide fragment of a substrate GPRP, a fibrinogen-like protein 1 (FGL1) containing the amino acid sequence, and a fibrinogen domain (FD) of the FGL1, where...
|
|
WO/2023/078821A1 |
In the management of patients with inflammatory bowel diseases (IBD), there is a need to identify druggable biological pathways to improve mucosal repair and efficacy of TNF alpha biologics. Based on the VIVA transgenic model of Vnn1 ove...
|
|
WO/2023/079187A1 |
The invention relates to a composition comprising a synergistic combination of fluoroethylnormemantine (FENM) and of at least one acetylcholinesterase inhibitor. More particularly, the invention relates to said composition for use thereo...
|
|
WO/2023/078180A1 |
The present invention belongs to the technical field of drugs, and specifically relates to a mini-tablet, and a preparation method therefor and a formulation thereof. The components of the mini-tablet comprises an active ingredient, a fi...
|
|
WO/2023/080703A1 |
The present invention pertains to a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients for prevention or treatment of cancer. The present invention can be advantageously use...
|
|
WO/2023/078426A1 |
Provided in the present invention are a compound, a pharmaceutical composition containing same, and the use thereof. The compound interferes with the interaction between the menin protein and MLL1 or MLL2 or a MLL fusion oncoprotein, and...
|
|
WO/2023/081801A2 |
Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients, wherein the patient is about 4 years old to less than about 12 years old. Provided herein are methods of using voxelotor for the treatme...
|
|
WO/2023/078941A1 |
The present invention relates to a new compound for the inhibition of the transmission of malaria in humans, a pharmaceutical composition comprising said compound, and a method for the inhibition of the transmission of malaria in humans ...
|
